Nuvation Bio (NUVB) Net Income towards Common Stockholders (2023 - 2025)
Historic Net Income towards Common Stockholders for Nuvation Bio (NUVB) over the last 3 years, with Q3 2025 value amounting to -$55.8 million.
- Nuvation Bio's Net Income towards Common Stockholders fell 3538.46% to -$55.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$217.5 million, marking a year-over-year increase of 5914.19%. This contributed to the annual value of -$567.9 million for FY2024, which is 64924.01% down from last year.
- Nuvation Bio's Net Income towards Common Stockholders amounted to -$55.8 million in Q3 2025, which was down 3538.46% from -$59.0 million recorded in Q2 2025.
- Nuvation Bio's 5-year Net Income towards Common Stockholders high stood at -$13.8 million for Q4 2023, and its period low was -$462.5 million during Q2 2024.
- Its 3-year average for Net Income towards Common Stockholders is -$73.8 million, with a median of -$41.2 million in 2024.
- As far as peak fluctuations go, Nuvation Bio's Net Income towards Common Stockholders crashed by 214075.58% in 2024, and later soared by 8724.15% in 2025.
- Nuvation Bio's Net Income towards Common Stockholders (Quarter) stood at -$13.8 million in 2023, then tumbled by 258.63% to -$49.4 million in 2024, then decreased by 12.84% to -$55.8 million in 2025.
- Its Net Income towards Common Stockholders was -$55.8 million in Q3 2025, compared to -$59.0 million in Q2 2025 and -$53.2 million in Q1 2025.